{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:47:15Z","timestamp":1785876435676,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007365","name":"Fondazione IRCCS Policlinico San Matteo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijcard.2026.134601","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:55:58Z","timestamp":1780530958000},"page":"134601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Use of cangrelor in patients with reduced renal function: Post-hoc analysis from the ARCANGELO study"],"prefix":"10.1016","volume":"460","author":[{"given":"Piera","family":"Capranzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Di Mario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Trani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Versaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Tomai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Pepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Cernetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plinio","family":"Cirillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2026.134601_bb0005","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel. Clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134601_bb0010","first-page":"441","article-title":"Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: the EYESHOT study","volume":"4","author":"de Luca","year":"2015","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"10.1016\/j.ijcard.2026.134601_bb0015","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"DL","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134601_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21301-5","article-title":"Renal metabolism and hypertension","volume":"12","author":"Tian","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijcard.2026.134601_bb0025","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/eurheartj\/ehab832","article-title":"Kidney function assessment and endpoint ascertainment in clinical trials","volume":"43","author":"Khan","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134601_bb0030","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1161\/CIRCULATIONAHA.111.084996","article-title":"Antithrombotic therapy in patients with chronic kidney disease","volume":"125","author":"Capodanno","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134601_bb0035","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.hlc.2013.03.005","article-title":"Myocardial revascularisation in renal dysfunction: a systematic review and meta-analysis","volume":"22","author":"Deo","year":"2013","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.ijcard.2026.134601_bb0040","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ijcard.2020.05.067","article-title":"Impact of renal function on the immediate and long-term outcomes of percutaneous recanalization of coronary chronic total occlusions: a systematic review and meta-analysis","volume":"317","author":"Moroni","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134601_bb0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000357399","article-title":"P2Y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa","volume":"127","author":"Alexopoulos","year":"2014","journal-title":"Cardiology"},{"key":"10.1016\/j.ijcard.2026.134601_bb0050","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1161\/CIRCULATIONAHA.118.032078","article-title":"P2Y12-ADP receptor blockade in chronic kidney disease patients with acute coronary syndromes","volume":"138","author":"Bonello","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134601_bb0055","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ehjcvp\/pvab042","article-title":"Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease","volume":"8","author":"Franchi","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.ijcard.2026.134601_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ehjcvp\/pvz048","article-title":"P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects","volume":"6","author":"De Filippo","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.ijcard.2026.134601_bb0065","doi-asserted-by":"crossref","first-page":"482","DOI":"10.5543\/tkda.2014.08838","article-title":"Efficacy and safety of antiplatelet drugs in patients with chronic kidney disease","volume":"42","author":"Yildiz","year":"2014","journal-title":"Turk Kardiyol. Dern. Ars."},{"key":"10.1016\/j.ijcard.2026.134601_bb0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/138920021602150713114437","article-title":"Evidence-based choice of P2Y12 inhibitors in end stage renal disease patients: a mini-review","volume":"16","author":"Bouatou","year":"2015","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ijcard.2026.134601_bb0075","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010394","article-title":"Temporal trends in utilization of cardiac therapies and outcomes for myocardial infarction by degree of chronic kidney disease: a report from the NCDR Chest Pain-MI Registry","volume":"7","author":"Bagai","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2026.134601_bb0080","series-title":"Kengrexal CHMP Annex I Summary of Product Characteristics","year":"2025"},{"key":"10.1016\/j.ijcard.2026.134601_bb0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0091270009344986","article-title":"Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist","volume":"50","author":"Akers","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ijcard.2026.134601_bb0090","first-page":"401","article-title":"Open Multicentre Study of the P2T Receptor Antagonist AR-C69931MX Assessing Safety","volume":"5","author":"Storey","year":"2001","journal-title":"Tolerability and Activity in Patients with Acute Coronary Syndromes. Thromb Haemost."},{"key":"10.1016\/j.ijcard.2026.134601_bb0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5603\/cj.96076","article-title":"Cangrelor - expanding therapeutic options in patients with acute coronary syndrome","volume":"31","author":"Kubica","year":"2024","journal-title":"Cardiol. J."},{"key":"10.1016\/j.ijcard.2026.134601_bb0100","doi-asserted-by":"crossref","DOI":"10.2174\/0115701611309982250522065849","article-title":"Transitioning from cangrelor to oral P2Y12 inhibitors in patients with ACS: insights from the ARCANGELO study","volume":"23","author":"De Luca","year":"2025","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2026.134601_bb0105","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead076","article-title":"Safety of cangrelor and transition to oral P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study","volume":"3","author":"De Luca","year":"2023","journal-title":"Eur. Heart J. Open"},{"key":"10.1016\/j.ijcard.2026.134601_bb0110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.amjcard.2024.12.021","article-title":"Use of cangrelor in older patients: findings from the Italian prospective study on CANGrELOr study","volume":"240","author":"Capranzano","year":"2025","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134601_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/clc.23878","article-title":"Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: study design and interim analysis of the ARCANGELO study","volume":"45","author":"De Luca","year":"2022","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134601_bb0125","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.ijcard.2026.134601_bb0130","series-title":"Bleeding Classification System Definitions","author":"Wells","year":"2019"},{"key":"10.1016\/j.ijcard.2026.134601_bb0135","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134601_bb0140","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"40","author":"Thygesen","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134601_bb0145","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2215\/CJN.02170218","article-title":"Clinical pharmacology of oral anticoagulants in patients with kidney disease","volume":"14","author":"Jain","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ijcard.2026.134601_bb0150","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.005257","article-title":"Cangrelor in older patients undergoing percutaneous coronary intervention: findings from CHAMPION PHOENIX","volume":"10","author":"Cavender","year":"2017","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2026.134601_bb0155","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jacc.2015.11.027","article-title":"Investigator-reported bleeding versus post hoc adjudication of bleeding: lessons from the CHAMPION PHOENIX trial","volume":"67","author":"Jatene","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134601_bb0160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0735-1097(17)33414-9","article-title":"Ischemic events occur early in patients undergoing Pci and are reduced with cangrelor: findings from Champion Phoenix","volume":"69","author":"Cavender","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134601_bb0165","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1161\/CIRCULATIONAHA.115.020829","article-title":"Consistent reduction in periprocedural myocardial infarction with cangrelor as assessed by multiple definitions: findings from CHAMPION PHOENIX (Cangrelor versus standard therapy to achieve optimal management of platelet inhibition)","volume":"134","author":"Cavender","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134601_bb0170","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function","volume":"122","author":"James","year":"2010","journal-title":"Circulation"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732600450X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732600450X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:07:20Z","timestamp":1785874040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752732600450X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"alternative-id":["S016752732600450X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134601","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of cangrelor in patients with reduced renal function: Post-hoc analysis from the ARCANGELO study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"134601"}}